Aducanumab FDA：Impacts of FDA approval and Medicare restriction on ...
Impacts of FDA approval and Medicare restriction on ...
由RBrockmann著作·2023·被引用26次—In2021,theUSFoodandDrugAdministration(FDA)grantedapprovaltoaducanumab,anantiamyloidantibodyforearly-stageAlzheimer'sdisease, ...。其他文章還包含有：「阿茲海默症重大里程碑！FDA核准第一個清除β類澱粉蛋白...」、「Aducanumab(marketedasAduhelm)Information」、「ADUHELM(aducanumab」、「AducanumabtoBeDiscontinuedasAlzheimer'sTreatment」、「Aninsider'sperspective...
查看更多 離開網站
阿茲海默症重大里程碑！ FDA 核准第一個清除β 類澱粉蛋白 ...
https://geneonline.news
6 月7 日，FDA 核准Aduhelm（aducanumab）治療阿茲海默症患者。 該藥是自2003 年以來第一個被核准的新療法，也是有史以來第一個證實透過清除β 類澱粉蛋白（amyloid beta, Aβ）減緩病情的療法。
Aducanumab (marketed as Aduhelm) Information
https://www.fda.gov
Aduhelm is an amyloid beta-directed antibody indicated to treat Alzheimer's disease. Aduhelm is approved under the accelerated approval ...
ADUHELM (aducanumab
https://www.accessdata.fda.gov
ADUHELM™ (aducanumab-avwa) injection, for intravenous use. Initial U.S. Approval: 2021. INDICATIONS AND USAGE. ADUHELM is an amyloid beta-directed antibody ...
Aducanumab to Be Discontinued as Alzheimer's Treatment
https://www.alz.org
According to the FDA, aducanumab reduces beta-amyloid plaques, which is reasonably likely to lead to a reduction in clinical decline due to Alzheimer's disease.
An insider's perspective on FDA approval of aducanumab
https://www.ncbi.nlm.nih.gov
Introduction. Aducanumab was approved in 2021 by the US Food and Drug Administration (FDA) under the accelerated approval pathway.
Aduhelm (aducanumab
https://www.drugs.com
On June 7, 2021, the FDA granted accelerated approval for Aduhelm (aducanumab-avwa) as the first and only Alzheimer's disease treatment to ...
Aduhelm
https://www.bmj.com
Aduhelm: Approval of Alzheimer's drug was highly unorthodox, finds report · FDA considers Alzheimer's drug previously abandoned for lack of ...
Approval of Aducanumab for Alzheimer Disease—The ...
https://jamanetwork.com
This Viewpoint discusses the rationale and data supporting the FDA's accelerated approval of aducanumab for Alzheimer disease treatment.
Aducanumab debate
https://www.medicalnewstoday.c
Now, a congressional report has accused the FDA of failing “to follow their own guidance and practices.” Aducanumab was approved despite ...